ARCHIVES

Arsenic Compound Improves Survival Of Adults With APL

This article is from The Cancer Letter archive.

Vol. 30 No. 2 | February 23, 2007

Download PDF Visit The Full Archive

Related Articles

ODAC Rejects Amsacrine NDA, Renews Idarubicin

September 14, 1990

John Durant Names ASCO Executive NP; A New Position, New Voice In Washington

December 2, 1994

NCI To Require Reports On Adverse Drug Reactions From Trials

June 10, 1994

Letter to the Editor: Could Managed care Cause Drop In Accrual In Suramin Trial?

January 5, 1996

FDA News: FDA Approved A Supplemental New Drug Application For Nexavar Tablets (Sorafenib) For The Treatment Of Patients With Locally Recurrent Or Metastatic, Progressive, Differentiated Thyroid Carcinoma Refractory To Radioactive Iodine Treatment.

December 17, 2013

Large Bowel Study Expansion Hampered By Lack Of Coordination, NCI Admits

May 17, 1974